Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer
British Journal of Cancer , Volume 100 - Issue 1 p. 13- 18
With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
|Hormone refractory prostate cancer, Novel therapeutics, PSA biomarker, Xenografts|
|British Journal of Cancer|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
van Weerden, W.M, Bangma, C.H, & de Wit, R. (2009). Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. British Journal of Cancer, 100(1), 13–18. doi:10.1038/sj.bjc.6604822